Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.50 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25691418 | 0.92 | CRBN (0.47) | CRBNDDB1BTKHPGDS | |
| SCHEMBL23133938 | 0.91 | CRBN (0.69) | CRBNDDB1BTKHPGDSIKZF3 | |
| SCHEMBL25691403 | 0.86 | CRBN (0.53) | CRBNDDB1BTKHPGDSALDH1A1 | |
| SCHEMBL21771313 | 0.83 | CRBN (0.65) | CRBNDDB1HPGDSIKZF3ALDH1A1 | |
| SCHEMBL23117898 | 0.83 | CRBN (0.58) | CRBNDDB1BTKHPGDS | |
| SCHEMBL29822185 | 0.83 | CRBN (0.58) | CRBNDDB1BTKHPGDS | |
| SCHEMBL25691400 | 0.82 | CRBN (0.46) | CRBNDDB1HPGDS | |
| SCHEMBL29821987 | 0.82 | CRBN (0.56) | CRBNDDB1BTKHPGDS | |
| SCHEMBL23117846 | 0.82 | CRBN (0.56) | CRBNDDB1BTKHPGDS | |
| SCHEMBL21771314 | 0.81 | CRBN (0.65) | CRBNDDB1HPGDSIKZF3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885DDB1 1112/4885BTK 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.